Trek Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Trek Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$277K	Buy	620 +27	+5%	+$12.6K	0.01%	399
2025 Q4	$269K	Buy	593 +37	+7%	+$15.9K	0.02%	379
2025 Q3	$218K	Buy	556 +20	+4%	+$8.36K	0.01%	405
2025 Q2	$239K	Buy	536 +23	+4%	+$10.6K	0.02%	377
2025 Q1	$249K	Buy	+513	New	+$239K	0.02%	341
2024 Q4	–	Sell	-439	Closed	-$204K	–	471
2024 Q3	$204K	Sell	439 -16	-4%	-$7.69K	0.02%	380
2024 Q2	$213K	Buy	+455	New	+$197K	0.02%	368
2024 Q1	–	Sell	-12,424	Closed	-$5.06M	–	440
2023 Q4	$5.06M	Buy	+12,424	New	+$4.59M	0.44%	54

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Trek Financial's VRTX Position: Q1 2026 in Review

Trek Financial increased its Vertex Pharmaceuticals (VRTX) stake by 4.6% in Q1 2026, buying an estimated $12.6K and bringing the position to 620 shares worth $277K. The position accounts for 0.01% of the portfolio, ranked #399.

Trek Financial first reported a position in VRTX in Q4 2023 and has held it in 8 quarters since. The position peaked at $5.06M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Trek Financial held 620 shares of Vertex Pharmaceuticals worth $277K as of Q1 2026.
Trek Financial bought 27 Vertex Pharmaceuticals shares in Q1 2026, an estimated $12.6K.
Vertex Pharmaceuticals made up 0.01% of Trek Financial's portfolio in Q1 2026, its #399 holding.
Trek Financial first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Trek Financial's Vertex Pharmaceuticals position peaked at $5.06M in Q4 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Trek Financial's 13F filing for Q1 2026, filed 13 May 2026.